Latest Headlines

Latest Headlines

FDA review drops a bombshell on Bayer, J&J anti-clotting drug Xarelto

The FDA dropped a bombshell on the anti-clotting drug Xarelto (rivaroxaban) this morning, noting in an agency review that Bayer ($BAYN) and Johnson & Johnson ($JNJ) had offered insufficient data

Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful

Bayer and its biotech partner Algeta took a big step today toward a relatively quick FDA decision on their closely-watched prostate cancer drug Alpharadin (radium-223 chloride). Regulators are

NEJM: Xarelto at least equal to warfarin

Bayer's new anti-clotting drug may not be superior to the old standby, warfarin, a new journal article suggests. But it is certainly just as good. And as co-author Gregory Zoppo told Reuters,

Bayer mulls bid for Pfizer's vet unit

Bayer CEO Marijn Dekkers says he's taking a look at bidding on Pfizer's ($PFE) animal health unit if the company decides to put it up for auction. The company is most interested in "smaller" deals

Bayer partners on Trius' Ph3 antibiotic in $94M pact

Eyeing the pharma prize in emerging markets, Bayer Pharma is partnering up with San Diego-based Trius Therapeutics on its lead antibiotic. The biotech reports that Bayer is handing over a $25 million

Study: MS drugs' benefits carry a steep price

A new study on the pricing of multiple sclerosis drugs--which found, essentially, that they're too expensive, at least in the U.S.--tags a few issues that people like to chat about casually. But what

Note to Pfizer: Bayer shopping for vet buys

Might Bayer be a potential buyer for Pfizer's ($PFE) animal health business? The German drugmaker wants to grow its animal health unit, research exec Andreas Busch tells Dow Jones. Part of that

As rumors swirl, Shire eyes Vyvanse for binge eating

Amid rumors that it's being targeted for takeover by Bayer, Shire is looking to develop its attention-deficit drug Vyvanse as a treatment for binge-eating disorder. The disorder is set to be

Bayer's Yasmin to face EU generics this year

Bayer's birth-control franchise suffered a blow in Europe as patent regulators yanked protection on Yasmin. As the company's second-best-selling drug, Yasmin could now face generic competition later

Bayer joins social media follies with tweet apology

Pharma's forays into social media have been tentative at best. Drugmakers never know when they'll take a step outside the lines. Consider Bayer, which was forced to apologize to U.K. watchdogs for